No Data Yet
Beijing-based biotech company Syneron Bio raised nearly $100 million in its Series A and A+ funding rounds to advance its Synova™ drug discovery platform.
A financial analysis on December 18, 2025, shows AstraZeneca stock is potentially 42.8% undervalued based on cash flow, despite a 35.1% annual gain and a P/E ratio suggesting fair value.
Niowave Inc. expanded its supply agreement with AstraZeneca to a 10-year commitment to deliver the medical isotope Actinium-225 for next-generation cancer therapies.
On December 18, 2025, Daiichi Sankyo and AstraZeneca's marketing application for their cancer drug DATROWAY was validated by the EMA, targeting the 70% of metastatic triple-negative breast cancer patients ineligible for immunotherapy.
Compugen monetized a portion of its future royalties for the cancer drug rilvegostomig to AstraZeneca for an upfront payment of $65 million, with the potential for an additional $25 million.
Guardant Health will present 14 studies at the 2025 San Antonio Breast Cancer Symposium on its liquid biopsy tests for breast cancer, aiming to validate their use in predicting recurrence and guiding treatment, positioning the company in the competitive oncology diagnostics market.
The U.S. FDA has approved a new combination therapy for HER2-positive metastatic breast cancer, positioning a treatment from AstraZeneca and Daiichi Sankyo as a new first-line standard of care. This decision is expected to significantly impact the treatment landscape and the market positions of the involved pharmaceutical companies.
GSK plc is gaining significant investor attention after a series of positive regulatory updates in the U.S. and EU for key pipeline assets. These catalysts, combined with an imminent CEO transition, are reshaping the company's narrative from a stable dividend stock to a growth-oriented pipeline story.
Hervé Hoppenot, Incyte's former Chairman and CEO, has resigned from the Board of Directors. The departure, though part of a planned transition, occurs as the broader biopharma industry grapples with significant executive turnover and profound regulatory uncertainty at the FDA.
A new report projects the global blood collection tubes market will reach $7.23 billion by 2032, driven by personalized medicine. However, this optimistic forecast is set against a backdrop of significant regulatory uncertainty at the U.S. Food and Drug Administration (FDA), creating a complex risk environment for key industry players like Becton Dickinson, Bio-Rad, and Thermo Fisher Scientific.
Major investment banks TD Cowen and Morgan Stanley have raised their price targets for AstraZeneca, citing a positive outlook. The move reflects strengthening institutional confidence in the pharmaceutical sector amid a broader trend of bullish analyst ratings across the market.
The market for carbon footprint management is projected to experience substantial growth, driven by stringent government regulations, rising industrial energy consumption, and mandatory corporate sustainability reporting. This expansion creates significant opportunities for technology providers and environmental consulting firms as industries globally race to decarbonize.
New drug pricing models from major insurers promise simplicity but face significant headwinds from a persistently complex and non-transparent healthcare system, leaving the potential for meaningful cost reductions uncertain.
Zealand Pharma announced its "Metabolic Frontier 2030" strategy and a potential $2.5B partnership with OTR Therapeutics. The move aims to challenge leaders Novo Nordisk and Eli Lilly in the rapidly fragmenting, $150B weight-loss drug market, despite a 29% year-to-date stock decline.
Portfolio
